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Inspiring Compassion for Rare Diseases
Colton Margus

When I was asked to contribute to this volume of Quill &
Scope, I was thrilled to have the opportunity to introduce Student Advocates for Neglected Diseases (STAND), the new
student group that I started here at New York Medical College to spur greater student engagement with this small and
most in-need patient community.
Despite what we learn in the classroom, many medical students across the country are not sufficiently exposed to and
thus not fully appreciative of the deeper burdens that patients
and families with rare and neglected diseases face. I want
STAND to address that, because I believe doing so will lead to
more informed and compassionate physicians.
Rare diseases are often life-threatening or chronically debilitating, and each rare disease affects a very small portion of the
population (fewer than 200,000 people in the United States).1
Neglected or orphan diseases include both rare inherited disorders as well as neglected infectious diseases affecting the
global poor. Such diseases are traditionally not given a high
priority for prevention or treatment and, as a result, lack sufficient attention from governments, healthcare professionals,
news media, and drug developers.
The Orphan Drug Act of 1983 and the subsequent Rare Diseases Act of 2002 exemplify laudable efforts to “promote the
development of drugs and devices for rare diseases” through
establishing a national office, increasing research funding,
and improving incentives for development of new therapies.1 However, the complexities of rare and neglected disease diagnosis at the level of individual patients and families
are still underappreciated within the medical profession.
At the heart of the matter is the belief that all patients should
matter. Neglected conditions have a harder time attracting
funding and support, and patients often suffer from that
oversight. Tens of millions of Americans are affected by nearly seven thousand rare diseases, most of which lack any treatment or cure. Their need for a helping hand does not depend
on disease prevalence—and neither should our compassion.
What should be great news for busy medical professionals
and students is that the smallest effort for the smallest communities can often make the biggest difference. Having an
impact on a rare disease does not necessarily mean finding a
cure. Coping with a rare disease can be incredibly isolating,
and an outstretched hand from the medical community can
mean the world. Just spending one-to-one time with the patients and their families and showing genuine interest in what
life is like for them can provide tremendous encouragement.
It can alleviate their feelings of being forgotten and provide
encouragement that the next generation of physicians will be
sensitive to their needs.
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Even beyond the orphan communities themselves, progress
on behalf of neglected diseases helps to advance the medical field more broadly. A substantial part of today’s medical
knowledge originated in the pursuit of an overlooked question or with a rare disease model.2 Future physicians must appreciate that neglected diseases can offer fertile opportunities
to advance innovative new research strategies and treatment
methods for more common disorders. In fact, as healthcare
management shifts toward personalized medicine targeting
smaller and smaller subsets of the general population,3 one
could argue that our research models developed on behalf of
rare disease communities will be all the more relevant.
I am admittedly biased—two of my younger brothers suffer
from a rare genetic disease called ataxia telangiectasia (AT). At a birth frequency of 1 in 300,000, my brothers’ autosomal recessive truncation of the ataxia telangiectasia mutated (ATM) gene is extremely rare, but no less devastating
in its stunted growth, progeric aging, cancer predisposition,
immune deficiency, and cerebellar degeneration.4 On top of
coping with their sons’ diminishing quality of life, my parents
have had to fight indifferent insurance companies and navigate enormous bureaucracies for support. I have seen doctors
misdiagnose and misguide treatment, but I have also seen
wonderful physicians listen carefully to my family’s concerns
and recognize the importance of collaborating with patients
and their families in managing a disease. I have seen the enormous difference a good physician can make to families like
mine, even when there is no cure.
Now that I am in medical school myself, I want to take the
opportunity to convince receptive future doctors of the value
in championing and understanding rare diseases just as they
begin their careers. I hope to plant the seed in the next generation of healthcare professionals by getting medical students
to think about and to engage with patient communities that
they might never come across otherwise.
STAND is busy organizing several events on campus to bring
attention to rare disease patients and their families. For example, following our introduction to the DNA-repair disorder xeroderma pigmentosum (XP) in our biochemistry
course last spring, we invited Caren Mahar, patient mother
and founder of the XP Society and Camp Sundown, to visit New York Medical College. It was a great opportunity for
students to hear a more personal perspective on the disorder,
and to better understand the often overlooked burdens on
families diagnosed with incurable diseases they cannot even
pronounce.
Still, as much as lectures and presentations raise awareness,
nothing compares to the effect that direct, individually-driven interactions can have on one’s outlook, investment, and
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propensity for future engagement. That is why STAND is
brainstorming more creative ways to get the student body directly involved with patients, both on campus and at other
medical institutions.
Our newly created “David R. Cox Prize for Rare Compassion”
will recognize the essays of student doctors who have most
inspiringly engaged a rare or neglected patient community
that they have encountered. Participating students will meet
with an unfamiliar patient, family, or advocate affected by a
rare disease, and share their newfound insights afterwards in
a short essay. Beyond that, it is also my hope that with help
from the Global Genes Project, an international organization,
we will be able to facilitate Rare Disease Day activities at medical schools around the country. There are a lot of exciting
directions we can go in.
Throughout this process, it has been overwhelming to see
how many people have come out of the woodwork for something meaningful. Even in the group’s infancy, we have already garnered the support of students, administrators, and
faculty alike, and their collective response has been more than
I could have hoped for.
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I feel incredibly fortunate and look forward to seeing the integration of our classroom foundations with rare disease advocacy and patient engagement. I am optimistic that our doing
so will make a positive difference in our community and in
how at least one doctor approaches patients and their families
somewhere down the road.
Author’s note: Associate Dean Tony Sozzo’s support has been
invaluable in the success of this student group, and a meeting
in January 2014 organized by Dr. Jennifer Koestler reiterated
the school’s commitment not only to supporting student initiatives but also to adapting the New York Medical College curriculum and learning experience in a way that will produce even
better doctors.
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